The Davenport FundAdvisor Q4 2024 Quarterly Update
The S&P 500 Index rose 25% in 2024, driven by strong earnings from tech stocks, especially the "Magnificent 7" benefiting ...
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.